IMvigor011: A Phase 3 Trial of ctDNA-Guided Adjuvant Atezolizumab versus Placebo in MIBC - report from ESMO 2025 episode artwork

EPISODE · Nov 14, 2025 · 7 MIN

IMvigor011: A Phase 3 Trial of ctDNA-Guided Adjuvant Atezolizumab versus Placebo in MIBC - report from ESMO 2025

from Medical Digest & Congress Report · host Medical Congress News

Professor Thomas B. Powles discuss the results from IMvigor011, a phase 3 trial of ctDNA-guided adjuvant atezolizumab versus placebo in muscle invasive bladder cancer were presented at the ESMO Congress 2025.Video: https://medicaldigest.org/scientific-contents/interview:imvigor011-phase-3-trial-ctdna-guided-adjuvant-atezolizumab-versus-placebo-mibc

Episode metadata supplied by the publisher feed · Published Nov 14, 2025

Embed this episode

Ready to play

IMvigor011: A Phase 3 Trial of ctDNA-Guided Adjuvant Atezolizumab versus Placebo in MIBC - report from ESMO 2025

0:00 7:09

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

Frequently Asked Questions

How long is this episode of Medical Digest & Congress Report?

This episode is 7 minutes long.

When was this Medical Digest & Congress Report episode published?

This episode was published on November 14, 2025.

Can I download this Medical Digest & Congress Report episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!